JPRN-jRCT2031220579CompletedPhase 1
A Phase 1 Study of Apraglutide (Single Dose Study)
Kozaki Tomohito0 sites36 target enrollmentStarted: January 22, 2023Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- Enrollment
- 36
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- >= 18age old to < 45age old (—)
- Sex
- All
Inclusion Criteria
- •The subjects will be individuals who meet all of the following criteria.
- •[1] Healthy Japanese men and women
- •[2] Individuals >=18 to <45 years of age at the time of informed consent
- •[3] Individuals who fully understand the details of the study and who are capable of providing written informed consent
Exclusion Criteria
- •Individuals meeting any of the following criteria will be excluded from the study.
- •[1] Past history of disease in organsystems considered unsuitable for this study
- •[2] Past history of disease or surgery that could affect pharmacokinetic or pharmacodynamic evaluation
- •[3] Other protocol defined exclusion criteria could apply
Investigators
Similar Trials
Completed
Phase 1
A pharmacokinetic study of novel formulations of ISC 17536 in healthy male adultsCTRI/2020/09/028094Glenmark Pharmaceuticals Ltd108
Recruiting
Not Applicable
Onderzoek naar aflevering van 124-I-F8IL10 in ontstoken gewrichten.Rheumatoid ArthritisNL-OMON28317VU University Medical Center5
Completed
Phase 1
A study in healthy volunteers to investigate how the test medicine CORT113176 is taken up by the body when given with food and without foodAmyotrophic lateral sclerosis (ALS)Nervous System DiseasesMotor neuron diseaseISRCTN52169163Corcept Therapeutics (United States)35
Recruiting
Phase 1
A Phase 1 Single Blind, Randomized, Single-Dose, Safety, Tolerability, Pharmacodynamic, and Pharmacokinetic Study of ZY7318 (pegylated recombinant human erythropoietin) in Healthy VolunteersHealthy volunteers study and investigational product would be targeted for secondary anemia due to renal cause.Renal and Urogenital - Kidney diseaseACTRN12613000374763Prolong Pharmaceuticals, LLC32
Completed
Not Applicable
A pilot study to evaluate the use of pregabalin in the management of burning mouth syndromeSigns and SymptomsBurning mouth syndromeISRCTN40332511Sheffield Teaching Hospitals NHS Foundation Trust (UK)20